Completed
A randomised, open-label, single-centre, drug-drug-interaction trial to evaluate the impact of carboxylesterase 2 (CES2)- and CYP3A4-inhibition on the pharmacokinetics of buloxibutid in healthy volunteers
2026-526135-18-00· Phase 1· Vicore Pharma AB· Source
Completed
An open, single arm, single-center, Phase 1 trial investigating the effect of 7-days-repeated administration of linaprazan glurate on the pharmacokinetics of repeated doses of an approved antibiotic in healthy participants
2024-518194-34-00· Phase 1· Cinclus Pharma Holding AB (publ)· Source
Completed
A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin
NCT07308041· Phase 1· Cinclus Pharma Holding AB· Source
Completed
A randomised, double-blind, placebo-controlled phase Ib trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ACD856 in healthy participants
2025-522287-32-00· Phase 1· AlzeCure Pharma AB· Source
Completed
A Phase 1/2a Study to Evaluate Single Intraarticular Injections of 3 Dose Levels of SYN321 and Placebo in Patients With Symptomatic Knee Osteoarthritis
NCT06989645· Phase 1/2· Synartro AB· Source
Not yet recruiting
A Trial With EMP16 in Preparation for Late Phase Studies
NCT06993428· Phase 2· Empros Pharma AB· Source
Completed
A phase 1, open-label trial in healthy subjects and in subjects with diabetes investigating pharmacokinetics, tolerability, safety, and food effect following single and multiple dosing of danegaptide
2024-515078-28-00· Phase 1· Breye Therapeutics ApS· Source
Completed
An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers
2024-514496-18-01· Phase 1· Disruptive Pharma AB· Source
Completed
An open-label, randomised, single-dose, three-way cross-over trial to assess the pharmacokinetics of NIC24-01 and NIC24-02 oromucosal pouches (a nicotine replacement therapy) in comparison to Nicorette® 4 mg gum in healthy adult smokers under fasted conditions.
2024-514676-40-00· Phase 1· Niconovum AB· Source
Completed
A Phase 2a, Randomised, Double-blind, Parallel and Placebo-controlled Trial Investigating Safety and Efficacy of LIB-01 in Treatment of Erectile Dysfunction
2024-515065-34-00· Phase 2· Dicot AB· Source
Active, not recruiting
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622· Phase 3· Boehringer Ingelheim· Source
Completed
A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis
2023-510249-79-00· Phase 2· Boehringer Ingelheim International GmbH· Source
Completed
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
NCT06335303· Phase 2· Boehringer Ingelheim· Source
Completed
SpinChip Hs-cTnI Determination of the 99th Percentile URL
NCT06463275· SpinChip Diagnostics ASA· Source
Completed
The Attractive 2 trial – An open-label, randomised, 2-period cross-over trial to assess the pharmacokinetics of ATR-258 oral capsule vs. oral solution formulations in healthy volunteers
2023-508797-28-00· Phase 1· Atrogi AB· Source
Completed
A24110He in a placebo-controlled trial evaluating safety in subjects with elevated plasma triglycerides
2023-509091-42-00· Phase 2· Lipigon Pharmaceuticals AB· Source
Completed
A phase 1, randomised, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics in healthy adult subjects after subcutaneous injection of TISA-818-Inj-5mg/mL.
2023-506912-41-00· Phase 1· Enlitisa (Shanghai) Pharmaceutical Co. Ltd.· Source
Completed
A randomised, placebo-controlled, double-blinded, cross-over, Phase 1 study evaluating the safety and preliminary efficacy of the GLP 1 analogue ROSE-010 on appetite and food intake in overweight and obese subjects.
2023-507758-34-00· Phase 1· Rose Pharma Inc.· Source
Completed
An open-label, healthy subject, two-part study to assess the effect of verapamil on systemic exposure of EP395 (Part A), and to assess the effect of EP395 on systemic exposure of midazolam and digoxin (Part B)
2023-506345-34-00· Phase 1· Epiendo Pharmaceuticals ehf.· Source
Active, not recruiting
A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight
NCT06151964· Phase 1/2· AstraZeneca· Source
Completed
Control Of BioEquivalence with Xenical (COBEX): A Phase I, randomized, active-control study to evaluate EMP22 pharmacodynamics and EMP16 pharmacokinetics versus Xenical® in healthy volunteers.
2023-505671-74-00· Phase 1· Empros Pharma AB· Source
Completed
A trial to evaluate safety and characteristics of a substance for treatment of chronic hepatitis
2023-503880-40-00· Phase 2· Suzhou Ribo Life Science Co. Ltd.· Source
Completed
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PARALLEL AND PLACEBO-CONTROLLED SINGLE AND MULTIPLE ASCENDING DOSE TRIAL INVESTIGATING SAFETY, TOLERABILITY AND PHARMACOKINETICS OF LIB-01 IN HEALTHY PARTICIPANTS
2023-505280-36-00· Phase 1· Dicot AB· Source
Completed
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
NCT05518123· Phase 4· Pfizer· Source
Completed
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
NCT05509400· Phase 4· Pfizer· Source
Completed
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
NCT04718389· Phase 3· GlaxoSmithKline· Source